{"id":"https://openalex.org/W2000200919","doi":"https://doi.org/10.1016/s1567-4215(03)90124-x","title":"197 Alterations in endothelin B receptor characteristics during the development of hypertension-induced cardiomyocyte hypertrophy are prevented by bosentan","display_name":"197 Alterations in endothelin B receptor characteristics during the development of hypertension-induced cardiomyocyte hypertrophy are prevented by bosentan","publication_year":2003,"publication_date":"2003-06-01","ids":{"openalex":"https://openalex.org/W2000200919","doi":"https://doi.org/10.1016/s1567-4215(03)90124-x","mag":"2000200919"},"language":"en","primary_location":{"id":"doi:10.1016/s1567-4215(03)90124-x","doi":"https://doi.org/10.1016/s1567-4215(03)90124-x","is_oa":false,"landing_page_url":"http://doi.org/10.1016/s1567-4215(03)90124-x","pdf_url":null,"source":{"id":"https://openalex.org/S207184414","display_name":"European Journal of Heart Failure Supplements","issn_l":"1567-4215","issn":["1567-4215","1878-1314"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Heart Failure Supplements","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058144680","display_name":"Gemma Beadnell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G BEADNELL","raw_affiliation_strings":["Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108565674","display_name":"Elizabeth J. Kelso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E KELSO","raw_affiliation_strings":["Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"middle","author":{"id":null,"display_name":"D BELL","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D BELL","raw_affiliation_strings":["Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003219291","display_name":"Doris Nicholls","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D NICHOLLS","raw_affiliation_strings":["Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111935904","display_name":"B. J. McDermott","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B MCDERMOTT","raw_affiliation_strings":["Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University Belfast, Therapeutics & Pharmacology, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I126231945"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"1","first_page":"40","last_page":"40"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10155","display_name":"Nitric Oxide and Endothelin Effects","score":0.948199987411499,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10155","display_name":"Nitric Oxide and Endothelin Effects","score":0.948199987411499,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11962","display_name":"Cardiac Fibrosis and Remodeling","score":0.013500000350177288,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.007400000002235174,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/endothelin-b-receptor","display_name":"endothelin B receptor","score":0.9879999756813049},{"id":"https://openalex.org/keywords/bosentan","display_name":"bosentan","score":0.8259999752044678},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.6449999809265137},{"id":"https://openalex.org/keywords/cardiomyocyte-hypertrophy","display_name":"cardiomyocyte hypertrophy","score":0.9769999980926514},{"id":"https://openalex.org/keywords/receptor-characteristics","display_name":"receptor characteristics","score":0.5899999737739563},{"id":"https://openalex.org/keywords/endothelin-receptor-antagonists","display_name":"endothelin receptor antagonists","score":0.6399999856948853},{"id":"https://openalex.org/keywords/heart-failure-prevention","display_name":"heart failure prevention","score":0.5580000281333923}],"concepts":[{"id":"https://openalex.org/C2781109936","wikidata":"https://www.wikidata.org/wiki/Q419769","display_name":"Bosentan","level":4,"score":0.9482192993164062},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9298726320266724},{"id":"https://openalex.org/C144980905","wikidata":"https://www.wikidata.org/wiki/Q24721308","display_name":"Endothelin receptor","level":3,"score":0.6829899549484253},{"id":"https://openalex.org/C2776345702","wikidata":"https://www.wikidata.org/wiki/Q390709","display_name":"Endothelin receptor antagonist","level":4,"score":0.6528059840202332},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.5966231822967529},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5945802330970764},{"id":"https://openalex.org/C167414201","wikidata":"https://www.wikidata.org/wiki/Q1955391","display_name":"Muscle hypertrophy","level":2,"score":0.5843353271484375},{"id":"https://openalex.org/C149601957","wikidata":"https://www.wikidata.org/wiki/Q390566","display_name":"Endothelin 1","level":3,"score":0.5145573019981384},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.40713173151016235},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3535182476043701}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s1567-4215(03)90124-x","doi":"https://doi.org/10.1016/s1567-4215(03)90124-x","is_oa":false,"landing_page_url":"http://doi.org/10.1016/s1567-4215(03)90124-x","pdf_url":null,"source":{"id":"https://openalex.org/S207184414","display_name":"European Journal of Heart Failure Supplements","issn_l":"1567-4215","issn":["1567-4215","1878-1314"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Heart Failure Supplements","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/2","display_name":"Zero hunger","score":0.4699999988079071}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2603796554","https://openalex.org/W2332545497","https://openalex.org/W2368336963","https://openalex.org/W2037999630","https://openalex.org/W2490499407","https://openalex.org/W2601112411","https://openalex.org/W2075542728","https://openalex.org/W2118208123","https://openalex.org/W2045303275","https://openalex.org/W2412463860"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}